Format

Send to

Choose Destination
Clin Cancer Res. 2015 Sep 1;21(17):3818-20. doi: 10.1158/1078-0432.CCR-15-1211. Epub 2015 Jul 13.

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.

Author information

1
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.
2
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu sarah.goldberg@yale.edu.
3
Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu sarah.goldberg@yale.edu.

Abstract

Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR can confer resistance that, depending on their genomic context, could determine new drug sensitivities of the cancer cells.

PMID:
26169963
PMCID:
PMC4720502
DOI:
10.1158/1078-0432.CCR-15-1211
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center